Genetic and clinical characteristics of moyamoya disease in europeans

Acta Neurochirurgica, Supplementum

Volumn , Issue 112, 2011, Pages 31-34

  Krischek, Boris ^a   Kasuya, Hidetoshi ^b   Khan, Nadia ^c   Tatagiba, Marcos ^a   Roder, Constantin ^a   Kraemer, Markus ^d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^d Alfried Krupp von Bohlen und Halbach Hospital   (Germany)

Author keywords

European; Genetics; Hemorrhage; Ischemia; Moyamoya disease

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CADHERIN; CHEMOKINE RECEPTOR CXCR4; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; ACTA2 PROTEIN, HUMAN; ACTIN; TGFB1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ASIAN; ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CAUCASIAN; CONFERENCE PAPER; CONSERVATIVE TREATMENT; EPILEPSY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HEADACHE; HYPERVENTILATION; MOYAMOYA DISEASE; PREVALENCE; RACE DIFFERENCE; RARE DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSIENT ISCHEMIC ATTACK; ARTICLE; CLINICAL TRIAL; EUROPE; GENETICS; HEALTH SURVEY; HUMAN; MULTICENTER STUDY;

ACTINS; EUROPE; GENETIC PREDISPOSITION TO DISEASE; HEALTH SURVEYS; HUMANS; MOYAMOYA DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79960662167     PISSN: 00651419     EISSN: 00016268     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0661-7_6     Document Type: Conference Paper

References (31)

1. Baba T, Houkin K, Kuroda S (2008) Novel epidemiological features of Moyamoya disease. J Neurol Neurosurg Psychiatry 79:900-904
2. Braun KP, Bulder MM, Chabrier S, Kirkham FJ, Uiterwaal CS, Tardieu M, Sebire G (2009) The course and outcome of unilateral intracranial arteriopathy in 79 children with ischaemic stroke. Brain 132:544-557
3. Chiu D, Shedden P, Grotta JC (1998) Clinical features of Moyamoya disease in the United States. Stroke 29:1347-1351 (Pubitemid 28300068)
4. Czabanka M, Pena-Tapia P, Schubert GA, Woitzik J, Horn P, Schmiedek P, Vajkoczy P (2009) Clinical implications of cortical microvasculature in adult Moyamoya disease. J Cereb Blood Flow Metab 29:1383-1387
5. Czabanka M, Vajkoczy P, Schmiedek P, Horn P (2009) Age-dependent revascularization patterns in the treatment of Moyamoya disease in a European patient population. Neurosurg Focus 26:E9
6. Goyal MS, Hallemeier CL, Zipfel GJ, Rich KM, Grubb RL Jr, Chicoine MR, Moran CJ, Cross DT 3rd, Dacey RG Jr, Derdeyn CP (2010) Clinical features and outcome in North American adults with idiopathic basal arterial occlusive disease without moyamoya collaterals. Neurosurgery 67:278-285
7. Graham JF, Matoba A (1997) A survey of Moyamoya disease in Hawaii. Clin Neurol Neurosurg 99(Suppl 2):S31-S35 (Pubitemid 27489059)
8. Guo DC, Papke CL, Tran-Fadulu V, Regalado ES, Avidan N, Johnson RJ, Kim DH, Pannu H, Willing MC, Sparks E, Pyeritz RE, Singh MN, Dalman RL, Grotta JC, Marian AJ, Boerwinkle EA, Frazier LQ, LeMaire SA, Coselli JS, Estrera AL, Saf HJ, Veeraraghavan S, Muzny DM, Wheeler DA, Willerson JT, Yu RK, Shete SS, Scherer SE, Raman CS, Buja LM, Milewicz DM (2009) Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet 84:617-627
9. Guzman R, Khan N, Steinberg G (2010) Moyamoya disease in North America. In: Cho B-K, Tominaga T (eds) Moyamoya disease update. Springer, New York
10. Guzman R, Lee M, Achrol A, Bell-Stephens T, Kelly M, Do HM, Marks MP, Steinberg GK (2009) Clinical outcome after 450 revas-cularization procedures for Moyamoya disease. Clinical article. J Neurosurg 111:927-935
11. Hallemeier CL, Rich KM, Grubb RL Jr, Chicoine MR, Moran CJ, Cross DT 3rd, Zipfel GJ, Dacey RG Jr, Derdeyn CP (2006) Clinical features and outcome in North American adults with moyamoya phenomenon. Stroke 37:1490-1496 (Pubitemid 44305731)
12. Hanggi D, Mehrkens JH, Schmid-Elsaesser R, Steiger HJ (2008) Results of direct and indirect revascularisation for adult European patients with Moyamoya angiopathy. Acta Neurochir Suppl 103:119-122
13. Imaizumi T, Hayashi K, Saito K, Osawa M, Fukuyama Y (1998) Long-term outcomes of pediatric Moyamoya disease monitored to adulthood. Pediatr Neurol 18:321-325 (Pubitemid 28191525)
14. Kelly ME, Bell-Stephens TE, Marks MP, Do HM, Steinberg GK (2006) Progression of unilateral Moyamoya disease: a clinical series. Cerebrovasc Dis 22:109-115 (Pubitemid 44114451)
15. Khan N, Schuknecht B, Boltshauser E, Capone A, Buck A, Imhof HG, Yonekawa Y (2003) Moyamoya disease and Moyamoya syn-drome: experience in Europe; choice of revascularisation proce-dures. Acta Neurochir (Wien) 145:1061-1071; discussion 1071 (Pubitemid 38091021)
16. Khan N, Yonekawa Y (2008) Moyamoya angiopathy in Europe: the beginnings in Zurich, practical lessons learned, increasing awareness and future perspectives. Acta Neurochir Suppl 103: 127-130
17. Kraemer M, Berlit P (2010) Primary central nervous system vasculitis and Moyamoya disease: similarities and differences. J Neurol 257:816-819
18. Kraemer M, Heienbrok W, Berlit P (2008) Moyamoya disease in Europeans. Stroke 39:3193-3200
19. Kuroda S, Ishikawa T, Houkin K, Nanba R, Hokari M, Iwasaki Y (2005) Incidence and clinical features of disease progression in adult Moyamoya disease. Stroke 36:2148-2153 (Pubitemid 41429236)
20. Kuroda S, Iwasaki Y (2006) Current review of familial Moyamoya disease. Nippon Rinsho 64(Suppl 8):750-754
21. Kuwabara Y, Ichiya Y, Sasaki M, Yoshida T, Masuda K, Matsushima T, Fukui M (1997) Response to hypercapnia in moyamoya disease. Cerebrovascular response to hypercapnia in pediatric and adult patients with Moyamoya disease. Stroke 28:701-707 (Pubitemid 27161449)
22. Numaguchi Y, Gonzalez CF, Davis PC, Monajati A, Afshani E, Chang J, Sutton CL, Lee RR, Shibata DK (1997) Moyamoya dis-ease in the United States. Clin Neurol Neurosurg 99(Suppl 2): S26-S30
23. Roder C, Nayak NR, Khan N, Tatagiba M, Inoue I, Krischek B (2010) Genetics of Moyamoya disease. J Hum Genet 55(11): 711-716
24. Roder C, Peters V, Kasuya H, Nishizawa T, Takehara Y, Berg D, Schulte C, Khan N, Tatagiba M, Krischek B (2010) Common genetic polymorphisms in Moyamoya and atherosclerotic disease in Europeans. Childs Nerv Syst 27(2):245-252
25. Roder C, Peters V, Kasuya H, Nishizawa T, Takehara Y, Berg D, Schulte C, Khan N, Tatagiba M, Krischek B (2010) Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients. Acta Neurochir (Wien) 152(12):2153-2160
26. Suzuki J, Kodama N (1983) Moyamoya disease: a review. Stroke 14:104-109
27. Tagawa T, Naritomi H, Mimaki T, Yabuuchi H, Sawada T (1987) Regional cerebral blood fow, clinical manifestations, and age in children with Moyamoya disease. Stroke 18:906-910 (Pubitemid 17126634)
28. Uchino K, Johnston SC, Becker KJ, Tirschwell DL (2005) Moyamoya disease in Washington state and California. Neurology 65:956-958 (Pubitemid 41362154)
29. Vajkoczy P (2009) Moyamoya disease: collateralization is every-thing. Cerebrovasc Dis 28:258
30. Yonekawa Y, Fandino J, Hug M, Wiesli M, Fujioka M, Khan N (2010) Moyamoya angiopathy in Europe. In: Cho B-K, Tominaga T (eds) Moyamoya disease update. Springer, New York
31. Yonekawa Y, Ogata N, Kaku Y, Taub E, Imhof HG (1997) Moyamoya disease in Europe, past and present status. Clin Neurol Neurosurg 99(Suppl 2):S58-S60 (Pubitemid 27489065)